<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4733">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01740102</url>
  </required_header>
  <id_info>
    <org_study_id>2011/2525</org_study_id>
    <nct_id>NCT01740102</nct_id>
  </id_info>
  <brief_title>Clinical Value of Remote Ischemic Preconditioning</brief_title>
  <official_title>Does Remote Ischemic Preconditioning Reduce the Incidence of Postoperative Atrial Fibrillation in Patient Undergoing Coronary Artery Bypass Graft Surgery?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Levanger Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Namsos Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Innlandet HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse MÃ¸re og Romsdal HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <authority>Norway:National Committee for Medical and Health Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: Despite utilization of available means for cardioprotection during cardiac
      surgery, myocardial injury still occurs. Further improvement of cardioprotection is
      therefore necessary. Remote ischemic preconditioning (RIPC) is an easy and non-invasive
      method. Laboratory research has shown promising results regarding myocardial survival during
      open heart surgery, but the clinical value of RIPC is still largely unknown. The
      investigators hypothesize that RIPC before coronary artery bypass grafting (CABG) reduces
      the incidence of postoperative atrial fibrillation (POAF).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Postoperative atrial fibrillation</measure>
    <time_frame>Up to 10 days after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>A patient will be classified as belonging to the postoperative atrial fibrillation group if they have any episode of atrial fibrillation, measured by telemetry, lasting more than 1 minute during their postoperative days at the hospital.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Maximum 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Heart Diseases</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>RIPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remote ischemic preconditioning (RIPC) in the operating theatre after induction of anaesthesia and before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No RIPC</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the control group will not receive remote ischemic preconditioning before the surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RIPC</intervention_name>
    <description>The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.</description>
    <arm_group_label>RIPC</arm_group_label>
    <other_name>Remote ischemic preconditioning</other_name>
    <other_name>Ischemic preconditioning</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective isolated on-pump CABG surgery

          -  Informed consent

        Exclusion Criteria:

          -  Patients with a severe pulmonary disease

          -  Patients with renal failure (GFR&lt;30 mL/min/1.73 m2)

          -  Patients with liver failure

          -  Peripheral vascular disease affecting the upper limbs

          -  Patients on sulfonylurea derivatives.

          -  Patients with atrial fibrillation in their case history

          -  Prior cardiac surgery (Re-operations)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Wahba, MD prof</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine Norwegian University of Science and Technology Trondheim, Norway, and Department of Cardiothoracic Surgery, St. Olavs Hospital, Trondheim, Norway.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Erik B Krogstad</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine Norwegian University of Science and Technology Trondheim, Norway.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Olavs Hospital Trondheim University Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 30, 2013</lastchanged_date>
  <firstreceived_date>November 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic preconditioning</keyword>
  <keyword>Coronary artery bypass</keyword>
  <keyword>Preoperative care</keyword>
  <keyword>Postoperative period</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
